Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12985380 | 1.00 | PKM (0.36) | PKMCYP4F2CYP4A11THRBHTT | |
| SCHEMBL13192842 | 1.00 | PKM (0.36) | PKMCYP4F2CYP4A11THRBHTT | |
| SCHEMBL15764443 | 1.00 | PKM (0.36) | PKMCYP4F2CYP4A11THRBHTT | |
| Bicarbonate SCHEMBL12988519 | 0.93 | PKM (0.32) | PKMCYP4F2CYP4A11THRBHTT | |
| SCHEMBL15764440 | 0.84 | CYP4F2 (0.36) | PKMCYP4F2CYP4A11THRBHTT | |
| SCHEMBL12985129 | 0.84 | CYP4F2 (0.36) | PKMCYP4F2CYP4A11THRBHTT | |
| SCHEMBL17830429 | 0.83 | PKM (0.38) | PKMCYP4F2CYP4A11THRBHTT | |
| SCHEMBL12985153 | 0.83 | PKM (0.38) | PKMCYP4F2CYP4A11THRBHTT | |
| SCHEMBL22446274 | 0.79 | PKM (0.39) | PKMCYP4F2CYP4A11THRBHTT | |
| SCHEMBL18978425 | 0.79 | PKM (0.39) | PKMCYP4F2CYP4A11THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468957-B1 | CRYSTALLINE FORM OF (R)-4-(5-(CYCLOPROPYLETHYNYL)ISOXAZOL-3-YL)-N-HYDROXY-2-METHYL-2-(METHYLSULFONYL)BUTANAMIDE AS AN ANTIBACTERIAL AGENT | NOVARTIS AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| EP-3233843-B1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS | NOVARTIS AG (CH) | 2019-10-16 | — | — | EP | disclosed |
| EP-3468957-A1 | CRYSTALLINE FORM OF (R)-4-(5-(CYCLOPROPYLETHYNYL)ISOXAZOL-3-YL)-N-HYDROXY-2-METHYL-2-(METHYLSULFONYL)BUTANAMIDE AS AN ANTIBACTERIAL AGENT | NOVARTIS AG (CH) | 2019-04-17 | — | — | EP | disclosed |
| US-10071973-B2 | Crystalline isoxazole hydroxamic acid compounds | NOVARTIS AG (CH) | 2018-09-11 | — | — | US | disclosed |
| US-10029994-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | NOVARTIS AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-20180030004-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-02-01 | — | — | US | disclosed |
| WO-2017216705-A1 | CRYSTALLINE FORM OF (R)-4-(5-(CYCLOPROPYLETHYNYL)ISOXAZOL-3-YL)-N-HYDROXY-2-METHYL-2-(METHYLSULFONYL)BUTANAMIDE AS AN ANTIBACTERIAL AGENT | NOVARTIS AG (CH) | 2017-12-21 | — | — | WO | disclosed |
| US-20170355684-A1 | CRYSTALLINE ISOXAZOLE HYDROXAMIC ACID COMPOUNDS | NOVARTIS PHARMA AG (CH) | 2017-12-14 | — | — | US | disclosed |
| US-9815804-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| EP-3233843-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS | Novartis AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| US-20170088525-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9549916-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | NOVARTIS AG (CH) | 2017-01-24 | — | — | US | disclosed |
| WO-2016097995-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-20160166548-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | NOVARTIS AG (CH) | 2016-06-16 | — | — | US | disclosed |
| EP-2694488-B1 | ISOXAZOLE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8748466-B2 | Isoxazole derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2694488-A1 | ISOXAZOLE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20140024690-A1 | Isoxazole Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2012137094-A1 | ISOXAZOLE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088525-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | LCT, AGXT, LPXN | PKM 2758/4885CYP4F2 2877/4885CYP4A11 4213/4885 |
| US-20160166548-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | LCT, AGXT, LPXN | PKM 2758/4885CYP4F2 2877/4885CYP4A11 4213/4885 |
| US-20170355684-A1 | CRYSTALLINE ISOXAZOLE HYDROXAMIC ACID COMPOUNDS | CUTA, MGAM, SQLE | PKM 2322/4885CYP4F2 2098/4885CYP4A11 1957/4885 |
| US-20180030004-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | LCT, AGXT, LPXN | PKM 2758/4885CYP4F2 2877/4885CYP4A11 4213/4885 |
| US-10029994-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | LCT, AGXT, LPXN | PKM 2758/4885CYP4F2 2877/4885CYP4A11 4213/4885 |
| US-10071973-B2 | Crystalline isoxazole hydroxamic acid compounds | CUTA, MGAM, SQLE | PKM 2322/4885CYP4F2 2098/4885CYP4A11 1957/4885 |
| US-20140024690-A1 | Isoxazole Derivatives Useful As Antibacterial Agents | HAX1, PRXL2A, PRDX1 | PKM 3306/4885CYP4F2 2372/4885CYP4A11 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.